Clinical trials: Cognitive Deficits, Mild
Mild Cognitive Impairment
MemoryXL Effects on Mild Cognitive Impairment Patients
A vitamin nutriceutical, Memory XL, has been shown to provide maintenance of cognitive status in mild, moderate, and severe Alzheimer's disease patients (2 publications by T. Shea).
- Trial name
- MemoryXL (NCT00903695)
- Testing
- Memory XL
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Oklahoma
Type 2 Diabetes, Mild Cognitive Impairment
Improving Medication Adherence in Older African Americans With Diabetes
This research aims to help older African Americans with diabetes and mild memory problems improve how they take their medications and control their diabetes.
- Trial name
- NCT02174562
- Testing
- Primary Care-Occupational Therapy, Enhanced Usual Care
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Thomas Jefferson University
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
This study evaluates the safety and effectiveness of intranasal (IN) glulisine in patients with amnestic mild cognitive impairment (aMCI) and probable Alzheimer's disease.
- Trial name
- NCT02503501
- Testing
- Insulin glulisine
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- HealthPartners Institute
Mild Cognitive Impairment
Memory Improvement Through Nicotine Dosing (MIND) Study
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI.
- Trial name
- MIND (NCT02720445)
- Testing
- Nicotine Transdermal Patch
- Where
- 36 sites in United States
- Volunteers
- 348 people
- Sponsor
- University of Southern California
Mild Cognitive Impairment
Impact of Combined Behavioral Interventions on Cognitive Outcomes in MCI
Vast evidence supports use of physical exercise and cognitive stimulation for lowering risk for cognitive decline and dementia, with combinations of non-pharmacological interventions providing greatest promise for impacting…
- Trial name
- CBI (NCT02864069)
- Testing
- Walking Intervention, Cognitive Training Intervention, Combined Intervention
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Dementia, Mild Cognitive Impairment
Repetitive Transcranial Magnetic Stimulation for Dementia
The purpose is to is to study if repetitive transcranial magnetic stimulation (rTMS) improves cognitive function in patients with neurodegenerative conditions which may manifest as mild to moderate cognitive impairment and, in…
- Trial name
- rTMS for demen (NCT02621424)
- Testing
- RTMS
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
- Trial name
- NCT02880956
- Testing
- ABBV-8E12
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Cognitive Impairment, Mild, Depressive Symptoms
Brain Stimulation and Enhancing Cognition in Older Adults
The aim of the current research is to evaluate the efficacy of a combination of Mindfulness-Based Stress Reduction (MBSR) and transcranial direct current stimulation (tDCS) to improve cognitive function in individuals with…
- Conditions
- Cognitive Impairment, Mild, Depressive Symptoms, Anxiety
- Trial name
- NCT03653351
- Testing
- Active Transcranial Direct Current Stimulation (tDCS)
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Mild Cognitive Impairment, Herpes Simplex 1
Valacyclovir for Mild Cognitive Impairment
Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI)…
- Conditions
- Mild Cognitive Impairment, Herpes Simplex 1, Herpes Simplex 2
- Trial name
- VALMCI (NCT04710030)
- Testing
- Valacyclovir hydrochloride 500mg caplet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- New York State Psychiatric Institute
Mild Cognitive Impairment
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
This study is intended to examine the impact of receiving a genetic risk assessment for Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01434667
- Testing
- APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
- Where
- 3 sites in United States
- Volunteers
- 146 people
- Sponsor
- Brigham and Women's Hospital
Alzheimers Disease, Postoperative Delirium
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
This study will examine the hypothesis that changes in the cognition (i.e. thinking and memory) after anesthesia and surgery are correlated with changes in markers of Alzheimers Disease in the fluid around the brain and spinal…
- Conditions
- Alzheimers Disease, Postoperative Delirium, Post Operative Cognitive Dysfunction
- Trial name
- MADCO-PC (NCT01993836)
- Testing
- Total intravenous anesthesia with propofol, General anesthesia with isoflurane
- Where
- United States
- Volunteers
- 191 people
- Sponsor
- Duke University
Mild Cognitive Impairment
Effects of Atomoxetine in Mild Cognitive Impairment
The purpose of this study is to evaluate the safety of atomoxetine and its effect primarily on the biologic markers (substances that may indicate the presence of a disease) in the cerebrospinal fluid (CSF) of participants…
- Trial name
- ATX-001 (NCT01522404)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Alzheimer's Disease, Mild Cognitive Impairment
Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.
When older patients develop cognitive problems - like memory loss - there may be any of several underlying causes, sometimes occurring in combination.
- Trial name
- NCT02309723
- Testing
- Beta amyloid imaging
- Where
- United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Parkinson Disease, Cognitive Impairment, Mild
Speech, Linguistic and Acoustic Markers in Parkinson's Disease
The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease.
- Conditions
- Parkinson Disease, Cognitive Impairment, Mild, Speech
- Trial name
- SLAM-PD (NCT04273672)
- Testing
- Cognitive Battery, Voice, Speech and Language Analysis, Questionnaires and Clinical Assessments
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Advanced Care Planning
A Portal-based Advance Care Planning Intervention Among Community-Dwelling Persons Living With Cognitive Impairment
The purpose of this research is to examine the feasibility of using a patient portal based advance care planning (ACP) tool to improve ACP discussions and documentation in persons living with cognitive impairment in outpatient…
- Trial name
- Portal-Voice (NCT06509373)
- Testing
- Advance Care Planning Tool - ACPVoice, Standard of Care for Advance Care Planning
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Wake Forest University Health Sciences
Alzheimer Disease, Mild Cognitive Impairment
Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.
- Trial name
- NCT04468347
- Testing
- Flortaucipir F18, Brain PET scan
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment
Using fMRI-guided TMS to Increase Central Executive Function in Older Adults (MCI_Sub)
This is an administrative supplement to an existing project "Using fMRI-guided TMS to increase central executive function in older adults: NCT02767323" This award allows extending our existing fMRI-TMS paradigm to patients with a…
- Trial name
- MCI_Sub (NCT04176406)
- Testing
- rTMS
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Duke University
Mild Cognitive Impairment, Dementia
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.
- Trial name
- NCT05104463
- Where
- 15 sites in United States, New Zealand
- Volunteers
- 64 people
- Sponsor
- CuraSen Therapeutics, Inc.